Crystalline MDM2 Inhibitor Intermediate for p53 Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for p53 wildtype (p53 WT< ) tumors, such as those involving MDM2 inhibitors, face challenges in selectively targeting and inhibiting the interaction between p53 and MDM2, which is crucial for activating p53 downstream effector genes and treating various cancers effectively.

Innovation Solution

A crystalline form of the intermediate 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid is developed, which inhibits the MDM2-p53 interaction, thereby activating p53 and treating p53 WT< tumors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If MDM2 inhibitors are used to treat p53 WT tumors, then the interaction between p53 and MDM2 is inhibited and p53 downstream effector genes are activated, but the selectivity and effectiveness of targeting this interaction remains challenging

Engineering Contradiction:

Improveeffectiveness of MDM2 inhibitionVSAvoidcomplexity of targeting p53-MDM2 interaction

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs parameter changes by developing a specific crystalline form of the MDM2 inhibitor intermediate with defined stereochemistry ((3R,5R,6S) configuration). This precise structural parameter optimization enables the compound to effectively bind to the MDM2-p53 interaction site, thereby improving the reliability of MDM2 inhibition while maintaining a manageable development process.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If a crystalline form of the intermediate is developed, then the MDM2-p53 interaction is effectively inhibited, but the manufacturing and purification processes become more complex

Engineering Contradiction:

Improveinhibition efficacy of MDM2-p53 interactionVSAvoidease of manufacturing crystalline intermediate

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent utilizes phase transitions by specifically developing a crystalline form of the MDM2 inhibitor intermediate. The crystalline structure provides enhanced stability and defined physical properties that facilitate purification and quality control. The patent describes methods to control the crystallization process to obtain the desired crystalline form with specific diffraction patterns, thereby improving inhibition efficacy while managing manufacturing complexity through controlled phase transition.

Inventive Principle:

Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The crystalline intermediate effectively inhibits the MDM2-p53 interaction, providing a targeted treatment approach for p53 WT< tumors, including solid and liquid tumors, with potential applications in treating a wide range of cancers.

Implementation Method 1

The crystalline intermediate effectively inhibits the MDM2-p53 interaction, providing a targeted treatment approach for p53 WT tumors

Methodology Applied

Scientific EffectMolecular binding:

Data Source

PatentEP3805232B1Crystalline synthetic intermediate useful in processes for making a MDM2 inhibitor

Publication Date: 2026.04.22 AMGEN INC

Figure 1
Figure 2
Figure 3

AI summary

The present invention provides the crystalline form of an intermediate useful in processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as processes for making the intermediate.